Investing.com - Financial Markets Worldwide
💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

ProQR's QR-110 Fast Track'd for rare pediatric blindness; shares ahead 3% premarket

Published 05/31/2017, 08:30 AM
© Reuters. ProQR's QR-110 Fast Track'd for rare pediatric blindness; shares ahead 3% premarket
PRQR
-
  • The FDA designates Orphan Drug-tagged ProQR Therapeutics' (NASDAQ:PRQR) QR-110 for Fast Track review for the treatment of Leber's Congenital Amaurosis Type 10 (LCA 10), a genetic disorder characterized by the progressive loss of vision in the first few years of life. It is caused by a mutation that results in abnormal splicing of messenger RNA (mRNA) which results in the non-functioning of a key protein called CEP920.
  • QR-110, an RNA-based oligonucleotide, is designed to restore the normal splicing of messenger RNA to enable fully functioning CEP920 to be produced. It is administered via intravitreal injections in the eye.
  • Fast Track status provides for more frequent interactions with the FDA review team and a rolling review of the New Drug Application (NDA).
  • Top-line results from an early-stage, open-label study, PQ-110-001, should be available next year.
  • Shares are up 3% premarket but only on 70 shares.
  • Now read: Heat Biologics (HTBX) Investor Presentation - Slideshow


Original article

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.